CMS Proposes Faster Drug Prior Authorization, 2.4% Inpatient Rate Increase, and Maryland Sets First State-Level Drug Price Cap
TODAY'S SIGNAL — A cluster of federal and state regulatory actions is reshaping the financial and operational landscape for healthcare organizations simultaneously.
CMS is moving on multiple fronts: proposing electronic prior authorization mandates with compressed timelines for prescription drugs, offering a 2.4% inpatient…
CMS is moving on multiple fronts: proposing electronic prior authorization mandates with compressed timelines for prescription drugs, offering a 2.4% inpatient payment bump, and greenlighting 150+ digital health companies for a chronic care experiment with outcome-aligned payments. Meanwhile, Maryland's affordability board has set the first state-level price cap on a medicine — targeting Jardiance for type 2 diabetes — establishing a precedent that other states with similar…
One pattern. Trace it.
- 01
A pattern worth naming
(2) CMS comment period activity on both the drug prior authorization rule and the 2.4% inpatient rate increase — hospital association and insurer lobbying positions will reveal likely final rule adjustments. (3) ACCESS experiment early participant performance data — CMS will likely publicize early metrics to build momentum for outcome-aligned payment models, potentially expanding the program in 2027.
“If Maryland's Jardiance cap works and Colorado follows with similar chronic disease drugs, which three formulary categories take the biggest margin hit?”
Ask your CFO whether the unit economics on every new service line still pencil under the new rate environment.
By Joseph Lancaster, Editor — with research from Pine Needle's intelligence layer.
The next argument lands tomorrow at 6 a.m. Pacific. Get it in your inbox →